Announcement under Regulation 30(LODR)-resignation of Chief Finance officer.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kimia Biosciences Ltd has informed the stock exchange about the resignation of its Chief Financial Officer, Mr. Rakesh Chetani. He submitted his resignation letter on April 22, 2025, citing personal reasons and his wish to pursue other professional opportunities. The company will relieve him from duties effective May 11, 2025, after the close of business hours. The disclosure confirms there are no material reasons for his exit beyond what is stated in his resignation letter. The company secretary, Pallavi Garg, has signed the intimation to BSE on April 23, 2025. No replacement CFO has been announced in this filing.
The CFO is a Key Managerial Personnel, so this is a notable leadership change for a small-cap company. Until a replacement is named, investors should watch for any update on the new CFO appointment, as prolonged vacancy in the finance function can affect financial reporting and compliance timelines. Near-term stock impact is likely muted unless concerns arise about the reasons for departure.